Naslov (eng)

Rivaroxaban versus dabigatran: a new era in venous thromboembolism treatment

Autor

Radak, Đorđe
Đukić, Nenad
Nešković, Mihailo
Babić, Srđan
Tanasković, Slobodan
Popov, Petar
Gajin, Predrag

Opis (eng)

SUMMARY: Considering the frequency of deep vein thrombosis and pulmonary embolism, the therapy of these two conditions takes an important place in vascular surgery. Among numerous therapeutic options, new oral anticoagulants, such as rivaroxaban or dabigatran, represent a great improvement in the treatment of venous thromboembolism. Searching MEDLINE base until December 1, 2015 using MESH term “Rivaroxaban versus Dabigatran in VTE”, we found 7 studies investigating the usage of new oral anticoagulants in venous thromboembolism treatment. The total of 18,841 patients was enrolled. No head–to–head studies were found. Benefits such as lower therapy price, oral use and greater comfort for patients and health providers place new oral anticoagulants to the frontline of venous thromboembolism treatment. However, we need head to-head studies to have a clear picture of these two drugs.

Opis (srp)

SAŽETAK: Uzimajući u obzir incidenciju tromboze dubokih vena i plućne embolije, terapija ovih stanja zauzima značajno mesto u vaskularnoj hirurgiji. Postoji više izbora lečenja, a novi oralni antikoagulansi, kao što su rivaroksaban i dabigatran, predstavljaju veliki pomak u terapiji venskih tromboembolijskih stanja. Pretražujući bazu podataka MEDLINE koristeći MESH izraz “Rivaroxaban versus Dabigatran in VTE” pronađeno je 7 studija sa ukupno 18841 ispitanikom. Nije pronađena nijedna studija koja direktno upoređuje upotrebu rivaroksabana i dabigatrana u terapiji venskih tromboembolijskih stanja. Oralna upotreba, niža cena lečenja kao i veći komfor za pacijente i lekare prednosti su novih oralnih antikoagulanasa u terapiji venskih tromboembolijskih stanja. Studije koje direktno uporedjuju Rivaroxaban i Dabigatran su neophodne radi boljeg razumevanja efekata ova dva leka.

Jezik

engleski

Datum

2016

Licenca

Ovo delo je licencirano pod uslovima licence
Creative Commons CC BY 4.0 - Creative Commons Autorstvo 4.0 International License.

https://scindeks.ceon.rs/JournalDetails.aspx?issn=0301-0619

Predmet

Key words: Rivaroxaban, Dabigatran, new oral anticoagulants, venous thromboembolism, deep vein thrombosis, pulmonary embolism

Ključne reči: Rivaroksaban, Dabigatran, novi oralni antikoagulansi, venski tromboembolizam, dubinska venska tromboza, embolija pluća

Deo kolekcije (1)

o:2793

Radovi saradnika Instituta za kardiovaskularne bolesti "Dedinje"